[The effect of proteinases and fibrinolysis inhibitors on experimental brain edema (author's transl)].
D000614:Aminocaproates / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D001929:Brain Edema / Q000188:drug therapy*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use; D004195:Disease Models, Animal; D006493:Heparin / Q000627:therapeutic use; D002542:Intracranial Embolism and Thrombosis / Q000139:chemically induced / Q000401:mortality; D008744:Methylamines / Q000009:adverse effects / Q000627:therapeutic use; D009942:Organometallic Compounds; D011480:Protease Inhibitors; D051381:Rats; D014001:Tin
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D003509:Cyclohexanecarboxylic Acids; D008744:Methylamines; D009942:Organometallic Compounds; D011480:Protease Inhibitors; D014001:Tin; D006493:Heparin; D007611:Aprotinin
Die Wirkung von Proteinasen und Fibrinolyse-Inhibitoren auf das experimentelle Hirnödem.